After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another...

Published on 20 Nov 2024 on Benzinga · via Yahoo Finance

On Wednesday, Sage Therapeutics Inc (NASDAQ:SAGE) revealed topline results from the Phase 2...

Read the rest of the article

Start tracking your investments with Statfolio

Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading...

Zacks · via Yahoo Finance 14 Jan 2025

U.S. stocks were mixed, with the Dow Jones index gaining over 200 points on Monday. Shares of Int...

Benzinga 13 Jan 2025

On Friday, Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitte...

Benzinga · via Yahoo Finance 13 Jan 2025

Shares of Sage Therapeutics Inc. surged after Biogen Inc. offered to acquire the...

Bloomberg 13 Jan 2025

Dozens of Massachusetts biotech leaders will be heading to San Francisco this upcoming week for t...

The Business Journals 12 Jan 2025

, opens new tab that it does not already own for $7.22 apiece, a filing showed on Friday, sending...

Reuters 10 Jan 2025

Dosing is expected to begin in the first quarter of 2025. JAZZ Wins Drug Approval Jazz...

Zacks · via Yahoo Finance 22 Nov 2024

On Wednesday, Sage Therapeutics Inc (NASDAQ:SAGE) revealed topline results from the Phase 2...

Benzinga · via Yahoo Finance 20 Nov 2024

Total Revenue: $22.1 million in Q3 2024. Collaboration Revenue: $11 million recognized by Sage fr...

GuruFocus.com · via Yahoo Finance 29 Oct 2024

LOS ANGELES, Oct. 21, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights...

The Longview News-Journal 21 Oct 2024